StreetInsider.com News Articles

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

Fri, 02 Oct 2026 11:57:00 -0400

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options
Towns shares why protecting his health remains

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

Fri, 02 Oct 2026 11:57:00 -0400

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options
Towns shares why protecting his health remains

Regeneron Pharma (REGN) PT Raised to $930 at Jefferies

Thu, 01 Oct 2026 12:43:33 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.

The analyst comments "REGN and SNY expanded their partnership around 4 next-gen type-2 inflammation assets, w/ REGN receiving $1B upfront + up to $7B milestones and 50/50 global economics. We see the deal as net +'ve for the co given better economics vs piror Dupi collab, a proven development & commercial playbook, sufficient time before Dupi LOE, and upside from lunsekimig optionality. Bottom line: REGN and SNY announced an expanded collaboration covering 4 next-gen antibodies (IL-13, IL-4xIL-13 bispecific, IL-4

Regeneron Pharma (REGN) PT Raised to $930 at Jefferies

Thu, 01 Oct 2026 12:43:33 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.

Regeneron Pharma (REGN) PT Raised to $930 at Jefferies

Thu, 01 Oct 2026 12:43:33 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.

Regeneron Pharma (REGN) PT Raised to $930 at Jefferies

Thu, 01 Oct 2026 12:43:33 -0400

Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.

Form 6-K Sanofi For: Oct 01

Thu, 01 Oct 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20261001/27134186.html

Form 6-K Sanofi For: Sep 17

Thu, 17 Sep 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260917/27072350.html

Sanofi to transfer 20 medicines and 3 plants to Cheplapharm

Mon, 14 Sep 2026 09:04:01 -0400

Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Cheplapharm announced a planned strategic partnership under which Cheplapharm would acquire 20 mature medicines and three manufacturing sites from Sanofi. In return, Sanofi would receive a 26.4% equity stake in Cheplapharm, according to a press release issued September 14, 2026.

The three manufacturing sites to be transferred include a facility in Csanyikvölgy, Hungary, employing approximately 400 people; a site in Jurong, Singapore, with around 100 employees; and a location in Ploërmel, France, with approximately 65 employees. Existing employment arrangements and collective agreements would be maintained at all three sites.

The medicines being transferred include Lovenox/Clexane (enoxaparin),

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Mon, 14 Sep 2026 09:03:00 -0400

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.
The partnership is based on a shared conviction: that innovative medicines and certain mature medicines have different needs and should benefit from operating models tailored

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Mon, 14 Sep 2026 09:03:00 -0400

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™

Thu, 10 Sep 2026 09:05:00 -0400

Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effects
The campaign serves up COVID-19 prevention education, including details about NUVAXOVID™ and its established tolerability

MORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi and USA Pickleball are teaming up to launch "Serve Up Protection," a campaign to educate older adults about COVID-19 and NUVAXOVID (COVID-19 Vaccine, Adjuvanted), the only protein-based, non-mRNA COVID-19 vaccine approved

Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™

Thu, 10 Sep 2026 09:05:00 -0400

Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effects
The campaign serves up COVID-19 prevention education, including details about NUVAXOVID™ and its established tolerability

Sanofi (SAN:FP) (SNY) PT Raised to EUR100 at HSBC

Thu, 10 Sep 2026 03:28:43 -0400

HSBC analyst Rajesh Kumar raised the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR100.00 (from EUR95.00) while maintaining a Buy rating.

Sanofi (SAN:FP) (SNY) PT Raised to EUR100 at HSBC

Thu, 10 Sep 2026 03:28:43 -0400

HSBC analyst Rajesh Kumar raised the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR100.00 (from EUR95.00) while maintaining a Buy rating.

Sanofi (SAN:FP) (SNY) PT Raised to EUR100 at HSBC

Thu, 10 Sep 2026 03:28:43 -0400

HSBC analyst Rajesh Kumar raised the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR100.00 (from EUR95.00) while maintaining a Buy rating.

Sanofi (SAN:FP) (SNY) PT Raised to EUR100 at HSBC

Thu, 10 Sep 2026 03:28:43 -0400

HSBC analyst Rajesh Kumar raised the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR100.00 (from EUR95.00) while maintaining a Buy rating.

RBC Capital Starts Sanofi (SAN:FP) (SNY) at Sector Perform

Wed, 09 Sep 2026 03:31:20 -0400